WO1988002406A3 - Procede de regulation de la stabilite metabolique de proteines - Google Patents

Procede de regulation de la stabilite metabolique de proteines Download PDF

Info

Publication number
WO1988002406A3
WO1988002406A3 PCT/US1987/002522 US8702522W WO8802406A3 WO 1988002406 A3 WO1988002406 A3 WO 1988002406A3 US 8702522 W US8702522 W US 8702522W WO 8802406 A3 WO8802406 A3 WO 8802406A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
methods
metabolic stability
proteins
amino
Prior art date
Application number
PCT/US1987/002522
Other languages
English (en)
Other versions
WO1988002406A2 (fr
Inventor
Andreas Bachmair
Daniel Finley
Alexander Varshavsky
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Priority to EP87907061A priority Critical patent/EP0324789B1/fr
Priority to AT87907061T priority patent/ATE247708T1/de
Priority to DE3752372T priority patent/DE3752372T2/de
Publication of WO1988002406A2 publication Critical patent/WO1988002406A2/fr
Publication of WO1988002406A3 publication Critical patent/WO1988002406A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Procédé permettant de concevoir ou de modifier une structure protéique au niveau protéique ou génétique pour produire des terminaisons amino spécifiques in vivo ou in vitro. Ces procédés peuvent être utilisés pour modifier la stabilité métabolique et d'autres propriétés de la protéine ou, alternativement, pour produire artificiellement des terminaisons amino authentiques dans des protéines produites par des moyens artificiels. Ces procédés se fondent sur l'introduction de l'utilisation de fusions protéine-ubiquitine artificielle, et sur la découverte que la demi-vie in vivo d'une protéine est une fonction de l'acide aminé de la terminaison amino de la protéine.
PCT/US1987/002522 1986-10-02 1987-10-01 Procede de regulation de la stabilite metabolique de proteines WO1988002406A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP87907061A EP0324789B1 (fr) 1986-10-02 1987-10-01 Procede de regulation de la stabilite metabolique de proteines
AT87907061T ATE247708T1 (de) 1986-10-02 1987-10-01 Verfahren zur regulierung der metabolischen stabilität von proteinen
DE3752372T DE3752372T2 (de) 1986-10-02 1987-10-01 Verfahren zur regulierung der metabolischen stabilität von proteinen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91515186A 1986-10-02 1986-10-02
US915,151 1986-10-02

Publications (2)

Publication Number Publication Date
WO1988002406A2 WO1988002406A2 (fr) 1988-04-07
WO1988002406A3 true WO1988002406A3 (fr) 1988-07-14

Family

ID=25435312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/002522 WO1988002406A2 (fr) 1986-10-02 1987-10-01 Procede de regulation de la stabilite metabolique de proteines

Country Status (6)

Country Link
EP (1) EP0324789B1 (fr)
JP (4) JP2612874B2 (fr)
AT (1) ATE247708T1 (fr)
CA (1) CA1313831C (fr)
DE (1) DE3752372T2 (fr)
WO (1) WO1988002406A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
US5156968A (en) * 1988-06-24 1992-10-20 Genentech, Inc. Purified yeast ubiquitin hydrolase
US5262322A (en) * 1988-06-24 1993-11-16 Genentech, Inc. Host transformed with yeast gene and ubiquitin/polypeptide fusions
CA2063400C (fr) * 1989-06-30 1997-07-15 David K. Gonda Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
US5620923A (en) * 1989-10-12 1997-04-15 The University Of Utah Synthesis of peptides as cloned ubiquitin extensions
DK0531404T3 (da) * 1990-05-09 1995-09-18 Massachusetts Inst Technology Ubiquitin-specifik protease
US5212058A (en) * 1990-05-09 1993-05-18 Massachusetts Institute Of Technology Nucleic acid encoding ubiquitin-specific proteases
ES2109336T3 (es) 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
WO1992022655A1 (fr) * 1991-06-10 1992-12-23 Lucky Limited Diagnostics de l'hepatite c et vaccin anti-hepatite c
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
DE69332377T2 (de) * 1992-07-13 2003-07-03 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
CA2146973C (fr) * 1992-10-29 2008-09-02 Patricia R. Segarini Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques
US5459051A (en) * 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO1996017941A2 (fr) * 1994-12-07 1996-06-13 Bionebraska, Inc. Production de peptides amides a l'extremite c-terminale a partir de produits de recombinaison proteiques
WO1999013077A2 (fr) * 1997-09-10 1999-03-18 President And Fellows Of Harvard College Procedes inductibles de repression de la fonction genique
EP2278006A3 (fr) 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261351A3 (fr) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
WO1999064583A2 (fr) * 1998-06-12 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services Compositions et procedes permettant de moduler la degradation proteolytique de cibles intracellulaires
DE69935857T2 (de) * 1998-07-10 2008-01-10 Calgene Llc, Davis Expression eukarotischer peptide in pflanzenplastiden
WO2000042185A1 (fr) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methodes pour reguler la stabilite de proteines recombinantes, et produits utilises dans ces methodes
EP2290083B1 (fr) 1999-04-30 2014-08-20 Novartis Vaccines and Diagnostics S.r.l. Antigènes conservés de Neisseria
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
BR0015137A (pt) 1999-10-29 2003-03-25 Chiron Spa Peptìdeos antigênicos de neisseria
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
MXPA02012292A (es) * 2000-06-15 2003-04-25 Smithkline Beecham Corp Metodo para preparar un polipeptido de factor de induccion de interferon-gamma (interleucina-18) fisiologicamente activo.
AU2002214127B2 (en) 2000-10-27 2007-06-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A and B
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002083907A1 (fr) * 2001-04-10 2002-10-24 Shionogi & Co., Ltd. Procede de production d'un polypeptide cible a l'aide de uspa
CA2469620A1 (fr) 2001-12-12 2003-06-19 Chiron Srl. Immunisation contre chlamydia trachomatis
CA2506318C (fr) 2002-11-15 2011-07-12 Chiron Srl Proteines de surface inattendues sur le meningocoque
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
RU2708160C2 (ru) 2015-06-11 2019-12-04 Дженексин, Инк. Модифицированный белок интерлейкина-7 и способы его применения
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
KR102604595B1 (ko) 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
KR20170066265A (ko) 2015-12-04 2017-06-14 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000831A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne d'un facteur de croissance semblable a l'insuline
WO1985004186A2 (fr) * 1984-03-16 1985-09-26 Biogen N.V. Interferon gamma modifie, sequences d'adn codant pour celui-ci e t ses procedes de production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572843D1 (en) * 1984-05-24 1989-10-12 Merck & Co Inc Site-specific proteolysis by renin
JPS62135500A (ja) * 1985-06-20 1987-06-18 モンサント　コンパニ− ポリペプチドからのペプチドの放出

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000831A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne d'un facteur de croissance semblable a l'insuline
WO1985004186A2 (fr) * 1984-03-16 1985-09-26 Biogen N.V. Interferon gamma modifie, sequences d'adn codant pour celui-ci e t ses procedes de production

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Nature, volume 309, 28 June 1984, K. Nagai et al.: "Generation of beta-globin by sequence-specific proteolysis of a hybrid protein produced in Escherichia coli" pages 810-812 see whole article, cited in the application *
Nucleic Acids Research, volume 13, no. 4, February 1985, IRL Press Ltd (Oxford, GB), B. Nilsson et al.: "Efficient secretion and purification of human insulin-like growth factor I with a gene fusion vector in Staphylococci", pages 1151-1162 see page 1153, line 20 - page 1158, line 20 *
Proc. Natl. Aca. Sci. USA, volume 81, November 1984, A. Hershko et al.: "Role of the alpha-amino group of protein in ubiquitin-mediated protein breakdown", pages 7021-7025 cited in the application *
Science, volume 198, no. 4321, 9 December 1977, K. Ikatura et al.: "Expression in Escherichia coli of a chemically synthesized gene for the hormaone somatostatin", pages 1056-1063 see the whole article *
Science, volume 234, no. 1883, 10 October 1986, A. Bachmair et al.: "In vivo half-life of a protein is a function of its amino-terminal residue", pages 179-186 see the whole article *

Also Published As

Publication number Publication date
EP0324789B1 (fr) 2003-08-20
CA1313831C (fr) 1993-02-23
JPH11187875A (ja) 1999-07-13
JPH02501618A (ja) 1990-06-07
ATE247708T1 (de) 2003-09-15
JPH08252096A (ja) 1996-10-01
JP2883594B2 (ja) 1999-04-19
DE3752372T2 (de) 2004-06-24
EP0324789A1 (fr) 1989-07-26
JP3038193B2 (ja) 2000-05-08
DE3752372D1 (de) 2003-09-25
JP2612874B2 (ja) 1997-05-21
JPH1057061A (ja) 1998-03-03
JP2776414B2 (ja) 1998-07-16
WO1988002406A2 (fr) 1988-04-07

Similar Documents

Publication Publication Date Title
WO1988002406A3 (fr) Procede de regulation de la stabilite metabolique de proteines
WO1989009829A3 (fr) Procedes de production de residus a terminaison amino dans des proteines
HK1008400A1 (en) Genetic modification of endothelial cells
EP1241258A3 (fr) Facteur de stimulation de cellules souches
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
WO1989009787A3 (fr) Dispositifs osteogeniques
EP0330451A3 (fr) CADN codant pour la sérumalbumine humaine normale et procédé de production de l'albumine
DE3852823T2 (de) Transduktionsveränderte fibroblasten und ihre anwendung.
AU2001278797A1 (en) Expression vector using for animal cell
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
DK684388A (da) Coekspression i eukaryote celler
CA2095852A1 (fr) Proteines a mutation d'epitopes; procede de fabrication
NZ217190A (en) Stable thrombin preparations
DK1394179T3 (da) Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner
EP0292965A3 (fr) Lignée de cellules humaines et triomes, anticorps et cellules transformées
ATE159297T1 (de) Expression von menschlichen serumalbumin in methylotrophischen hefen
HK206196A (en) Acid-labile subunit (ALS) of insulin-like-growth factor (IGF) binding protein complex
AU1141288A (en) Production of proteins in active forms
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
DE69425809T2 (de) Methoden zur Herstellung von Protein C
MX9704780A (es) Antigeno de fas humano secretado.
JPS5731622A (en) Production of human somatropin
DE69032471D1 (de) Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
DK171489A (da) Peptidderivater
AU8217487A (en) Process for the cultivation of mammalian cells in a suspension culture, device for carrying out the process, and use for the preparation of proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987907061

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987907061

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1987907061

Country of ref document: EP